The pharmaceutical market in the UAE is poised for significant growth, driven by the government’s robust healthcare commitment, a rising population, and increasing healthcare needs, according to an industry expert.
Globalpharma, a subsidiary of Dubai Investments and a prominent player in the Dubai Financial Market, actively supports national initiatives such as Operation 300bn and the Make it in the Emirates vision. “Through strategic partnerships, we are enhancing localization efforts, expanding operations, and strengthening the UAE’s domestic supply chain,” said Basem Al Barahmeh, General Manager of Globalpharma, in an interview with Khaleej Times.
Globalpharma’s UAE sales surged 16% year-on-year to $49 million this year, as per company data. The company’s focus areas underscore its dedication to supporting the UAE’s strategic industrial growth and self-reliance. By boosting local manufacturing capabilities, Globalpharma offers a wide range of high-quality, affordable medications, contributing to a robust industrial ecosystem. Through fostering partnerships and strengthening the domestic supply chain, the company reduces reliance on imports, thereby enhancing the UAE’s economic resilience and industrial advancement.
The synergy with Dubai Investments has further empowered Globalpharma to invest in cutting-edge research and development, driving innovation, and creating advanced therapies that position the UAE as a leader in pharmaceutical excellence. “Additionally, we pioneer innovative formulations and localize advanced technologies to optimize therapeutic outcomes and directly support the Make it in the Emirates initiative, paving the way for a future-ready industrial sector,” Al Barahmeh noted.
Globalpharma remains steadfast in its commitment to the UAE’s vision of becoming a regional pharmaceutical hub. “Our efforts aim to drive this transformation by attracting foreign investment, partnering with international pharmaceutical companies, and developing local talent through robust training programs,” Al Barahmeh said. The company’s success has inspired more firms to manufacture products in the UAE, reducing reliance on imports and solidifying the UAE’s position as a global pharmaceutical leader.
Globalpharma’s strategic focus includes fostering international collaborations, such as its long-standing partnership with GSK. “Through this collaboration, we have localized the production of key medicines, particularly in the anti-infective category, contributing to the UAE’s self-sufficiency in essential healthcare products,” Al Barahmeh explained. The company has also ventured into herbal medicines, producing two new herbal products locally, which marks a significant step in diversifying its offerings.
The company continues to pursue strategic partnerships with international pharmaceutical companies to integrate advanced manufacturing processes and cutting-edge technologies. “These collaborations aim to accelerate innovation by fostering joint research and development initiatives, enabling the faster introduction of new therapies to benefit patients in the UAE and the wider region,” Al Barahmeh added. Expanding local manufacturing remains a cornerstone of Globalpharma’s strategy, reducing reliance on imports and offering high-quality medications at more accessible prices.
Source link: https://www.khaleejtimes.com
